INDUSTRY NEWS

Stay up-to-date on the latest industry, member, and policy related news.

MichBio members can submit news to be shared here, on our social media, and in our monthly newsletter.

New Funding Opportunity from the NIH: Small Business Transition Grant For Early Career Scientists

July 8, 2022

The National Cancer Institute (NCI) recently released a new funding opportunity for biotech companies and university researchers! The new Small Business Transition Grant funds the translation of technology from university to small business, as well as the transition of early career researchers from academia to industry. This award uses the Small Business Technology Transfer (STTR)…

Recent White House Proposals on Cancer Research Would be Counterproductive

July 7, 2022

Earlier this year, the Biden Administration aimed to reignite the Cancer Moonshot through its proposed federal budget and an objective to reduce cancer mortality by 50% over the next 25 years. The White House proposes to increase public funding for cancer research and at the same time control the price of cancer treatments. A University…

PODCAST: Accelerated Approval Study and Implications for Rare Disease Patients

July 7, 2022

This podcast discusses the results of Vital Transformation’s latest research study outlining the impact of proposed changes to the Accelerated Approval pathway, and what this would mean for patients with rare conditions. The study quantifies the impact of the Accelerated Approval pathway in bringing new therapies for unmet needs to market, and the vital role…

Multi-Cancer Early Detection Screening Coverage Act

July 7, 2022

MichBio is among over 400 groups from all 50 states that have signed the Prevent Cancer Foundation’s letter to Congress encouraging passage of the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 1946 / S. 1873). The legislation has reached an exciting milestone with over half of the U.S. House of Representatives having co-sponsored the bill. As a reminder,…

Cybersecurity Front and Center for Feds

July 7, 2022

Congress is considering several pieces of legislation requiring the FDA to regularly update cybersecurity guidance and better coordinate efforts with other agencies to better safeguard of medical and healthcare technologies from digital threats. A bipartisan proposal, the Strengthening Cybersecurity for Medical Devices Act, would require the agency to review and update premarket medical device cybersecurity guidance…

Senate Committee Advances PBM Transparency Legislation

July 7, 2022

The Senate Commerce Committee passed legislation, Pharmacy Benefit Manager Transparency Act of 2022 (S. 4293) , that is designed to address how PBMs control drug prices and can potentially reduce the amount independent pharmacies and consumers pay for medicine. PBMs manage prescription drug benefits for insurance plans and payers. They receive rebates and discounts on…

UFAs Advance Slowly

July 7, 2022

Reauthorization of the FDA user fee agreement (UFA) package – that sets terms, conditions and costs for review of prescription drug (PDUFA), medical device (MDUFA), generic drug (GDUFA), and biosimilar (BsUFA) applications – is inching forward in Congress. In addition to codifying the agreements, these bills are often vehicles for other FDA policy changes. On…

Grand River Aseptic Manufacturing Invests $160 Million with Award from U.S. Government to Support Continued and Future Growth

June 2, 2022

Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense. Under the agreement, GRAM will invest $160 million and receive $120 million from the U.S. government to fund the expansions of…

Gilbert Foundation invests $18M toward Gene Therapy Initiative

June 2, 2022

Original Source The Gilbert Family Foundation, a private fund established by Dan and Jennifer Gilbert, announced Thursday it is funding more than $18 million in grants toward a cure for Type 1 neurofibromatosis. The money will fund a three-year campaign as part of the organization’s Gene Therapy Initiative. Four grants totaling $4.4 million will be invested…

U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

June 2, 2022

Original Source   Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5…

Vestaron Closes Series C Funding at $82M

June 2, 2022

May 16, 2022 – (RTP, North Carolina) – Vestaron, a leader in peptide-based biological crop protection, is pleased to announce the official closing of the Series C fundraising efforts at $82M as of May 12, 2022. The financing was significantly oversubscribed with high demand from both existing and new investors. Lead investors joining Vestaron in…

Michigan Awarded More Than $236 Million to Support Small Businesses, Create Jobs and Grow Michigan’s Economy

June 2, 2022

Governor Gretchen Whitmer joined the Michigan Economic Development Corporation (MEDC) to announce that Michigan has been approved for up to $236,990,950 in State Small Business Credit Initiative (SSBCI) funding from the U.S. Department of Treasury. “Ensuring small businesses can thrive and create good-paying jobs in every region of Michigan is critical as we continue growing…

Phenomics Health Advances Precision Medicine with Products that Integrate Medication Selection, Adherence, Dose Tailoring and Monitoring

June 2, 2022

Plymouth, MI – May 23, 2022 – Phenomics Health Inc., a bioinformatics-based precision medicine company, today announced the commercial integration of six PrecīsMed® pharmacometabolomic (PMx) and PredictScript™ pharmacogenomic (PGx) clinical products to comprehensively support individual patient medication treatment. Phenomics Health novel product platforms can now provide clinicians with multiple tools to enhance treatment outcomes through…

MMS Holdings Selects THREAD as Partner of Choice to Deliver Decentralized Clinical Trials

June 2, 2022

CANTON, Mich. (05/24/2022) – MMS Holdings Inc. (MMS) – an award-winning, data-focused contract research organization (CRO) – announced a collaboration with THREAD® as its partner of choice for its decentralized clinical trial platform (DCT) and DCT-enabled services. THREAD’s next-generation DCT technology enables faster, more efficient clinical trials while improving access for research participants with higher quality data…

UFAs on the Docket

May 31, 2022

The U.S. House Energy and Commerce (E&C) Health Subcommittee on Wednesday advanced to the full committee legislation reauthorizing user fee programs, including PDUFA and MDUFA. The legislation, H.R. 7667, the Food and Drug Amendment Act, passed 30-0 on a bipartisan vote with provisions to increase clinical trial diversity, modify the accelerated approval pathway and promote generics. On the…